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Objectives We aimed to identify risk factors for recurrent syncope in children and adolescents with congenital long QT
syndrome (LQTS).
Background Data regarding risk assessment in LQTS after the occurrence of the first syncope episode are limited.
Methods The Prentice-Williams-Peterson conditional gap time model was used to identify risk factors for recurrent syn-
cope from birth through age 20 years among 1,648 patients from the International Long QT Syndrome Registry.
Results Multivariate analysis demonstrated that corrected QT interval (QTc) duration (500 ms) was a significant predic-
tor of a first syncope episode (hazard ratio: 2.16), whereas QTc effect was attenuated when the end points of
the second, third, and fourth syncope episodes were evaluated (hazard ratios: 1.29, 0.99, 0.90, respectively; p 
0.001 for the null hypothesis that all 4 hazard ratios are identical). A genotype-specific subanalysis showed that
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0.001) but exhibited similar rates of subsequent events as other genotype-sex subsets (p  0.63). In contrast, in
the age range of 13 to 20 years, long QT syndrome type 2 females experienced the highest rate of both first and
subsequent syncope events (p  0.001 and p  0.01, respectively). Patients who experienced 1 episodes of
syncope had a 6- to 12-fold (p  0.001 for all) increase in the risk of subsequent fatal/near-fatal events inde-
pendently of QTc duration. Beta-blocker therapy was associated with a significant reduction in the risk of recur-
rent syncope and subsequent fatal/near-fatal events.
Conclusions Children and adolescents who present after an episode of syncope should be considered to be at a high risk of
the development of subsequent syncope episodes and fatal/near-fatal events regardless of QTc duration.
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LQTS and Recurrent Syncope February 22, 2011:941–50Congenital long QT syndrome
(LQTS) is an inherited cardiac
arrhythmic disorder due to mu-
tations affecting the cardiac ion
channels resulting in delayed
ventricular repolarization and a
prolonged QT interval on an
electrocardiogram (ECG). The
associated arrhythmias may man-
ifest as syncope, aborted cardiac
arrest, or sudden cardiac death
(SCD).
Thus far, studies on the risk
stratification of LQTS have pro-
vided data on the clinical and
genetic risk factors predicting the
likelihood of a first cardiac event
(1–3). However, these studies
may not apply to patients with
LQTS who present after their
first episode of syncope. Specifically, children and adoles-
cents with congenital LQTS were shown to have a high risk
of a first cardiac event. However, currently, there are no data
regarding risk factors for recurrent episodes of syncope in
this population. We hypothesized that the traditional clin-
ical, electrocardiographic, and genetic risk factors for a first
syncope would exhibit a time-dependent change in predic-
tive value for recurrent syncope. Accordingly, the primary
aim of the present study was to investigate risk factors for
recurrent syncope in children and adolescents who present
for evaluation after a syncope episode. To further stress the
importance of recurring syncope as a risk factor in LQTS,
we also assessed the risk of fatal or near-fatal events after
repeated episodes of syncope in this population.
Methods
Study population. The study population was drawn from
the International LQTS Registry. Patients were included in
the study if they had: 1) a corrected QT interval (QTc)
duration assessed using Bazett’s formula (4) of 450 ms;
and/or 2) a documented LQTS-causing mutation by ge-
netic testing. Subjects were excluded from the analysis if
they: 1) had a QTc duration450 ms on the baseline ECG
without a genotype-positive mutation; 2) were from families
with known LQTS mutations but did not have their
family’s LQTS mutation (the exclusion of such individuals
might involve rare patients with an undetected second
mutation); and 3) were enrolled in the registry after 20 years
of age to enable complete data collection regarding events
that occurred during the childhood and adolescence periods.
The final sample consisted of 1,648 patients.
Data collection and management. On enrollment, a com-
plete medical history was obtained, and patients were
followed yearly for additional medical information. Prospec-
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrome
LQT1  long QT syndrome
type 1
LQT2  long QT syndrome
type 2
PWP  Prentice, Williams,
and Peterson
QTc  corrected QT
interval
SCD  sudden cardiac
deathtively designed forms were used to obtain clinical data frompatients, their families, and physicians (by regular phone
and mail contact), regarding individual and family history,
demographic, electrocardiographic, therapeutic, and cardiac
event information. On enrollment in the International
LQTS Registry, a 12-lead ECG was obtained for each
subject. Lead II was used for measuring the QT interval,
which was adjusted for heart rate by Bazett’s formula (4).
Information on LQTS therapies was gathered prospectively
at yearly intervals. Follow-up data regarding beta-blocker
therapy included the starting date, type of beta-blocker, and
discontinuation date in case it occurred. Among subjects
who died, the use of a beta-blocker before death was
determined retrospectively.
The LQTS genotype was determined by multiple estab-
lished genetic laboratories using standard mutational ana-
lytic techniques. In this study sample, 738 patients were
genetically tested and identified to have an LQTS-causing
mutation. The LQTS Registry study was approved by the
University of Rochester Institutional Review Board, and
informed consent was obtained from study participants or
their guardians. The first recorded ECG obtained at the
time of patient enrollment in the LQTS Registry was used
in the current analysis.
End points. The primary end point was the occurrence of
recurrent syncope episodes after the first event (categorized
as second through fourth episodes) from birth through age
20 years. Syncope was defined as a transient loss of con-
sciousness with abrupt onset and offset. A subsequent
syncope episode was defined as syncope occurring 7 days
from the previous syncope episode. The 7-day separation
period was included to distinguish a single event from a
continuing event associated with specific triggers (i.e., fever,
menses, medications), allowing patients to be clearly re-
moved from the triggered event and stabilized on new
therapies. Aborted cardiac arrest (ACA) and LQTS-related
SCD served as end points for our analysis of the association
between recurrent syncope and the risk of subsequent fatal
or near-fatal events. ACA was defined as cardiac arrest with
recovery after defibrillation, and SCD was defined as sudden
and unexpected death due to LQTS.
Statistical analysis. The clinical characteristics of the study
patients were categorized by the total number of syncope
episodes experienced by the patients. Patients with different
numbers of syncope episodes were compared using the
chi-square test for categorical variables and analysis of
variance for continuous variables.
The conditional model, proposed by Prentice, Williams,
and Peterson (PWP), was used to simultaneously model the
distribution of the time to first syncope episode and the gap
times between subsequent syncope events as functions of
risk factors of interest (5), with inference based on the
robust sandwich estimator of the covariance matrix for the
estimated model parameters to account for potential depen-
dencies between the gap times. Unlike some other models
for recurrent events, such as the marginal model of Wei et
al. (6), the PWP model assumes that the risk of a second
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February 22, 2011:941–50 LQTS and Recurrent Syncopeevent is conditional on having a first event. Each ordered
outcome (first, second, third, and fourth syncope episodes)
is assigned to a separate time-dependent stratum, with its
own baseline hazard function, and all covariates are inter-
acted with each stratum, allowing each ordered outcome to
effectively have its own unconstrained Cox model. Pre-
specified covariates that were included as potential predic-
tors of a first and recurrent syncope episodes included sex,
age older than 13 years (except for the first syncope episode,
where this main effect term was absorbed by the baseline
hazard function because age is the time scale), sex  age
older than 13 years interaction (to allow for separate hazard
ratios for males and females among those younger than 13
and those 13 years of age and older [1]), the Bazett-
corrected QT interval (dichotomized at QTc duration500
ms in the primary analysis, and at the upper quartile [540
ms] in a secondary analysis), and beta-blocker therapy
(modeled as a time-dependent binary covariate).
We also performed a genotype-specific subset analysis
among the 644 long QT type 1 syndrome (LQT1) or long
QT type 2 syndrome (LQT2) study patients to identify
potential genotype-sex factors as predictors of the first and
subsequent episodes of syncope. We focused on the LQT1
and LQT2 genotypes due to the limited number of patients
with the other genotypes. Because previous studies showed
a relationship between genotype, sex, and age (1), we
performed Kaplan-Meier estimates of time to first and
second events based on genotype-sex subsets (categorized as
LQT1 males, LQT1 females, LQT2 males, and LQT2
Clinical and Electrocardiographic CharacteristicNumber of Syncope Epis des During Follow-Up (Table 1 C inical n El ctro ardiograph c CNumber of Syncope Episodes During
Characteristic 0
n 965
Male 515 (53) 11
Congenital deafness 6 (1)
Electrocardiogram (ms)
QRS 76 15 77
R-R 695 205 819
QTc duration, ms 478 41 502
QTc 500 ms 174 18 87
LQTS-related therapies
Beta-blockers 566 (59) 21
ICD 59 (6) 5
PM 30 (3) 2
LCSD 6 (1)
Fatal/near-fatal events during
follow-up‡
ACA 27 (3) 2
SCD 34 (4) 1
Data are shown as n (%) or mean  SD. *p value 0.05 for the diffe
events); findings were similar when a p value for trend was assessed.
‡No statistical test was performed to compare the frequency of fatal/
time in each subset. Adjusted results for the difference are shown in
ACA  aborted cardiac arrest; ICD  implantable cardioverter-defi
SCD  sudden cardiac death; QTc  corrected QT interval.females) and within pre-specified age groups (childhood: age 0 tto 12 years; adolescence: age 13 to 20 years), with the log-rank
test used for hypothesis testing. Multivariate analyses of these
interactions were performed to analyze genotype and sex
interactions within age groups. Due to a smaller sample size of
genotyped patients, we limited the analyses in the genotype-
specific models to a comparison of risk factors for the first and
the second syncope episodes (i.e., all subsequent episodes were
categorized into a single 2 events end point).
Wald tests were used for each joint hypothesis test that
etermined whether the covariate by event stratum interac-
ions was significant.
The Cox model was used to evaluate the association be-
ween first and recurrent syncope episodes and the risk of
ubsequent ACA or SCD. The same covariates used to model
ecurrent syncope in the PWP model were used in this
nalysis, with the addition of the time-dependent number of
revious syncope events. The Kaplan-Meier estimator was
sed to assess the 5-year cumulative probability of an ACA or
CD based on combined assessment of the number of syncope
pisodes experienced by an individual and QTc duration.
Statistical analysis was performed using SAS version
.1.3 for Windows (SAS Institute, Cary, North Carolina).
esults
he clinical characteristics of the total study cohort and the
enotype-positive patient subset by the number of episodes
f syncope during follow-up are shown in Tables 1 and 2,
espectively. Comparison of electrocardiographic parame-
the1,648)teristics by the
ow-Up (n  1,648)
umber of Episodes of Syncope
2 3 >4
151 99 192
74 (49) 40 (40) 79 (41)
6 (4) 7 (7) 23 (12)*†
78 17 78 16 75 15
6 820 218 832 218 865 208*
514 61 511 57 514 60*†
64 43 40 40 78 41*
136 (90) 90 (91) 186 (97)*†
31 (21) 29 (29) 51 (27)*
25 (17) 18 (18) 40 (21)*†
2 (1) 11 (11) 44 (23)*†
16 (11) 16 (16) 30 (16)
10 (7) 10 (10) 21 (11)
mong the 5 subgroups (comprising no syncope and 1 to 4 syncopal
e 0.05 for the difference among the 4 syncopal events subgroups.
tal events among the syncope subgroups due to a different follow-up
.
r; LCSD  left cardiac sympathetic denervation; PM  pacemaker;s byn harac
Foll
N
1
241
9 (49)
6 (2)
 18
 23
 54
 36
3 (88)
7 (24)
7 (11)
7 (3)
3 (10)
3 (5)
rence a
†p valu
near-fa
Table 4ers showed increasing QTc duration with an increasing
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LQTS and Recurrent Syncope February 22, 2011:941–50number of syncope episodes. Notably, patients who experi-
enced syncope had a very high frequency of beta-blocker use
(88%). In addition, the frequency of implantable
ardioverter-defibrillator (ICD) use was significantly higher
mong patients who experienced syncope, but similar
mong the 4 syncope subgroups (Table 1). Among the 738
enotype-positive patients, the LQT1 and LQT2 genotypes
omposed the majority (87%) identified LQTS genotypes
Table 2). The mean ages at which the first through fourth
pisodes of syncope occurred were 9, 10, 11, and 12 years
6 years for all), respectively, and the majority (80%) of
ubsequent events occurred within 5 years of the previous
vent. The frequency of patients who experienced1 syncope
vents was similar between LQTS patients who did and did
ot undergo genetic testing (37% and 42%, respectively).
isk factors for first and recurrent episodes of syncope.
atients with QTc duration 500 ms had a significantly
igher cumulative probability of experiencing their first
yncope as compared to patients with QTc duration 500
s (75% vs. 48%, respectively; p  0.001) from birth
hrough age 20 years (Fig. 1A). However, among patients
ho experienced a first syncope, the rate of subsequent
vents was increased among those who had both QTc
uration 500 ms and those with QTc duration 500 ms
74% and 76%, respectively; p  0.11) at age 20 years
Fig. 1B). Similarly, among patients who experienced 2, 3,
nd 4 syncope episodes, the risk of a subsequent syncope
pisode was virtually identical between patients who had
arrow or prolonged QTc duration (not shown). This was
upported by the PWP model for recurrent events (Table 3),
hich showed that QTc duration 500 ms was a powerful
ndependent predictor (2-fold risk increase; p  0.001) of
first syncope episode, whereas the risk associated with
Tc duration was significantly attenuated when the end
oints of subsequent episodes of syncope were assessed
second syncope episode, hazard ratio [HR]: 1.29; third
yncope episode, HR: 0.99; fourth syncope episode, HR:
.90; interaction p  0.001 for the null hypothesis that all
HRs are identical). The results regarding the association
etween QTc duration and the risk of a first episode and
Clinical and Electrocardiographic CharacteristicSy cope Episodes During Follow-Up: Genotype-PTable 2 C inical n Electro ardiograph c CSyncope Episodes During Follow-Up
Number of
0 1
n 467 115
LQT1 236 (51) 54 (47)
LQT2 161 (34) 41 (36)
LQT3 59 (13) 15 (13)
LQT5–8 5 (1) 2 (2)
1 mutations† 6 (1) 3 (2)
Values are n (%) unless otherwise specified. *p value for the overa
subgroups. †Includes patients who were genetically tested and identi
LQT1 long QT syndrome type 1; LQT2 long QT syndrome type 2; L
long QT syndrome types 5 through 8.ecurrent events were virtually identical when patients with wongenital deafness (n  48) and multiple mutations (n 
7) were excluded from the analysis. Furthermore, a sec-
ndary analysis, in which QTc duration was categorized at
he upper quartile of the study population (540 ms [n 
25]) or as a continuous measure, consistently demonstrated
hat QTc was predictive only of a first event and not of
ubsequent events (not shown).
A sex-genotype specific analysis that was performed in a
ubset of 644 patients having either the LQT1 (n  387) or
QT2 (n 257) genotype showed age-dependent risk factors
or first and subsequent cardiac events (Figs. 2 and 3). During
hildhood, males with LQT1 had the highest cumulative
robability for a first cardiac event (36% during 10 years of
ollow-up [Fig. 2A]). In contrast, after the occurrence of a first
vent, the cumulative probability of a subsequent event during
hildhood was increased substantially in all genotype-sex
ubgroups (35% to 46% during only 2 years of follow-up
Fig. 2B]). Consistent with these findings, multivariate analysis
howed that during childhood, males with LQT1 exhibited a
ignificant increase in the risk of a first syncope episode (p 
.001 for the overall difference among the subgroups) but did
ot show a statistically significant increase in the risk of
ubsequent events (p  0.34 for the overall difference among
he subgroups).
After the onset of adolescence, there was an age-sex risk
eversal, and females with LQT2 showed the highest rate of
oth a first cardiac event (38% during 5 years of follow-up
Fig. 3A]) and subsequent events (58% during only 2 years
f follow-up [Fig. 3B]). Similarly, multivariate analysis
howed that females with the LQT2 genotype in the age
ange of 13 through 20 years exhibited a higher risk of both
first and subsequent events compared with the other
ex-genotype groups (p  0.001 and p  0.02, respectively,
or the overall difference).
ecurrent syncope and the risk of subsequent ACA or SCD.
fter adjustment for QTc duration, sex, and time-
ependent beta-blocker therapy, the occurrence of recurring
pisodes of syncope was associated with a pronounced
ncrease in the risk of subsequent ACA or SCD (Table 4).
ompared with no events, having 1 or 2 syncope episodes
the Number ofve Patients (n 738)teristics by the Number of
otype-Positive Patients (n 738)
des of Syncope
p Value*3 >4
8 35 63
(52) 14 (40) 40 (63)
(35) 17 (48) 15 (24)
(3) 1 (3) 3 (5) 0.04
(5) 2 (6) 1 (2)
(5) 1 (3) 4 (6)
ence for the distribution of genotypes among the syncope episode
having 1 LQTS-causing mutation.
long QT syndrome type 3; LQT3 long QT syndrome type 3; LST5–8s byositiharac
: Gen
Episo
2
5
30
20
2
3
3
ll differ
fied asas associated with a 6-fold (p  0.001) increased risk of
s
a
d
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February 22, 2011:941–50 LQTS and Recurrent Syncopesubsequent ACA or SCD, and having 2 episodes was
associated with a 12-fold (p  0.001) relative risk of
ubsequent fatal or near-fatal events (Table 4). Combined
ssessment of the number of syncope episodes and QTc
uration (Fig. 4) showed that the 5-year cumulative prob-
Figure 1 Probability of Cardiac Events by QTc Duration
Kaplan-Meier estimates of the probability of a first episode, of syncope (with follow
patients who experienced a first syncope episode, with follow-up time starting at t
(dichotomized at 500 ms).
Multivariate Analysis (Total Population): PredictSyncopal Events*Table 3 Multivariate Analysis (T tal opulaSyncopal Events*
End Point
QTc Duration (>500 ms vs. <5
HR† 95% CI
First event 2.14 1.84–2.49
Second event 1.32 1.07–1.62
Third event 1.10 0.85–1.43
Fourth event 1.01 0.82–1.26
*See the Methods section for description of analytic technique; finding
and sex  age interaction. †Omnibus p value for testing the null hypo
null hypothesis that all 4 HRs are 0.001. ‡Omnibus p value for testi
null hypothesis that all 4 HRs are 0.001.
CI  confidence interval.ability of ACA or SCD was lowest among those who did
not experience syncope (1% and 5% in patients with QTc
duration500 ms and500 ms, respectively), intermediate
among those who experienced 1 or 2 syncope episodes (11%
to 14%), and highest among those who experienced 2
e starting at birth) (A) and a second episode of syncope (among
e of the first syncope event) (B) by corrected QT interval (QTc) duration
f First and RecurrentPredictors of First and Recurrent
) Time-Dependent Beta-Blocker Effect
lue HR‡ 95% CI p Value
01 0.54 0.42–0.70 0.001
09 0.22 0.17–0.28 0.001
7 0.35 0.27–0.46 0.001
1 0.44 0.35–0.54 0.001
urther adjusted for corrected QT interval (QTc) duration500ms, sex,
that all 4 hazard ratios (HRs) equal 1 0.001; p value for testing the
null hypothesis that all 4 HRs equal 1 0.001; p value for testing the-up tim
he timors oion):
00 ms
p Va
0.0
0.0
0.4
0.9
s were f
thesis
ng the
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LQTS and Recurrent Syncope February 22, 2011:941–50syncope episodes (17% to 21%). Notably, the effect of QTc
duration on the risk of subsequent ACA or SCD was
pronounced before the occurrence of a first syncope episode
and attenuated after the occurrence of syncope (Fig. 4).
Beta-blocker therapy. Beta-blocker use was associated in-
Figure 2 Cumulative Probability of First and Second Syncope E
Kaplan-Meier estimates of the probability of a first (A) and second (B) syncope ep
with follow-up time starting at the time of the first event) in genotype-sex subsets
LQT1  long QT syndrome type 1; LQT2  long QT syndrome type 2.dependently with a significant and a substantial reduction inthe risk of both first and recurrent syncope episodes
(Table 2). The magnitude of risk reduction associated with
beta-blocker therapy was similar in LQT1 and LQT2
patients. Furthermore, treatment with beta-blockers was
associated with a significant (70%) reduction in the risk of
es by Sex and Genotype During Childhood
(among patients who experienced a first event,
age range of 0 through 10 years. CE  cardiac event;pisod
isode
in thesubsequent fatal or near-fatal events among patients who
947JACC Vol. 57, No. 8, 2011 Liu et al.
February 22, 2011:941–50 LQTS and Recurrent Syncopeexperienced a first episode and recurrent episodes of syncope
(Table 3).
Discussion
Previous studies on risk stratification in LQTS have been
limited to identifying markers that predict the risk of a first
Figure 3 Cumulative Probability of First and Second Syncope E
Kaplan-Meier estimates of the probability of a first (A) and a second (B) syncope
with follow-up time starting at the time of the first event) in genotype-sex subsetscardiac event. Our study is the first to assess traditional riskmarkers for cardiac events in the LQTS populations as
independent predictors of subsequent syncope. Unlike pre-
vious studies, we assessed recurrent syncope as an end point
rather than a risk factor. We have shown that, in children
and adolescents with congenital LQTS, there are important
time-dependent changes in risk factors after a first syncope
es by Sex and Genotype During Adolescence
e (among patients who experienced the first event,
age range of 13 to 20 years. Abbreviations as in Figure 2.pisod
episod
in theepisode. Importantly, the present study shows that the risk
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LQTS and Recurrent Syncope February 22, 2011:941–50of subsequent syncope episodes after the occurrence of a first
event is increased regardless of QTc duration, despite the
high use of beta-blocker therapy (90%) during this time
period. Furthermore, our results confirm that recurrent
syncope is a powerful predictor of subsequent fatal or
near-fatal events, independently of QTc. These findings
have important clinical and therapeutic implications for
LQTS patients who present for evaluation after the occur-
rence of a first episode of syncope before 20 years of age.
QTc duration as a risk marker for first and recurrent events.
The heart rate–QTc interval has been the basis for diag-
nostic criteria for LQTS (7) and is a known predictor of a
first cardiac event in this population (3,8–11). Our results
are consistent with previous observations, demonstrating
that a QTc duration of 500 ms is an independent
predictor of a first cardiac event. However, an LQTS
patient who has already experienced a syncope episode
should be considered at higher risk of a recurrent syncope
episode and possibly even LQT-triggered ACA/SCD re-
gardless of his or her QTc value. Notably, the proportion of
patients with a lower-range QTc duration in the total
population (65%) was higher than among patients who
experienced recurrent events (approximately 50%). How-
Multivariate Analysis (Cox Model): Recurrent Syncope as a PredictTable 4 Multivariate Analysis (Cox Model): Recurrent Syncope
Variable
Adjusted Ris
HR‡ 95% CI
First syncope event vs. no events 6.54 3.96–10.80
Second syncope event vs. no events 6.69 6.65–12.25
Third syncope event vs. no events 12.51 7.03–22.28
4 Syncope events vs. no events 14.65 8.02–26.76
*Adjusted for significant covariates: QTc duration 500 ms, sex, age, sex  age interaction, and
risk of the end point in each risk group was evaluated by including a beta-blocker  syncope grou
HRs equal 1  0.001; p value for testing the null hypothesis that all 4 HRs equal  0.016. §Om
hypothesis that all 4 HRs  0.959.
Abbreviations as in Table 3.
Figure 4 The 5-Year Cumulative Probability of ACA/SCD by
the Number of Syncope Episodes and QTc Duration
Kaplan-Meier estimates of the 5-year cumulative probability of aborted cardiac
arrest (ACA) and sudden cardiac death (SCD) before the occurrence of a first
episode of syncope and after the first, second, third, and fourth episodes of
syncope by corrected QT interval (QTc) duration. Follow-up was restarted after
the occurrence of a syncopal event.ever, although in the former subgroup, a QTc 500 ms is
indicative of a relatively lower risk of a first cardiac event
(3,8–11), it is not a reassuring value after the occurrence of
an LQTS cardiac event. It is possible that additional risk
factors may be present in LQTS patients who present with
a first syncope episode despite a lower-range QTc duration,
including environmental factors, the presence of modifier
genes, or high-risk ion channel properties of the LQTS-
related mutation. Thus, risk assessment and management of
clinically symptomatic children and adolescents with con-
genital LQTS should be independent of QTc. This impact
on risk stratification requires careful evaluation to distin-
guish whether that first event stemmed from LQT’s signa-
ture dysrhythmia of torsades or whether that fainting
episode was simply a vasovagally mediated episode occur-
ring in an LQTS host.
Sex, genotype, and age as risk markers for first and
recurrent events. The effect of sex, genotype, and age on
time to the first cardiac event has been well studied (1,7–9).
During childhood, males with LQTS were shown to have
an increased risk of a first cardiac event compared with their
female counterparts (12) and to experience the events at a
younger age (1). After the onset of adolescence, however,
risk reversal occurs, and females were shown to exhibit a 2-
to 3-fold increased risk of a first cardiac event compared
with males throughout adulthood (10,12). Previous studies
have also shown that there are also important genotype-sex
interactions within the age groups. Thus, during childhood,
males with LQT1 were shown to be at higher risk of a first
cardiac event, whereas after the onset of adolescence, LQT2
females were shown to exhibit a higher risk (1,12). Consis-
tent with previous data, our genotype-specific analysis also
shows that males with LQT1 and females with LQT2
experienced the highest rate of first events during childhood
and after the onset of adolescence, respectively. However,
our findings extend those of previous studies and demon-
strate that after the occurrence of a first cardiac event, rates
are markedly increased during childhood regardless of
genotype or sex (35% in all genotype-sex during only 2
years of follow-up), whereas the risk of recurrent events
during the post-adolescence period remains higher among
females with LQT2. Notably, women with the LQT2
ACA/SCD*Predictor of ACA/SCD*
Time-Dependent Beta-Blocker Effect†
p Value HR§ 95% CI p Value
0.001 0.25 0.11–0.55 0.001
0.001 0.28 0.11–0.72 0.008
0.001 0.22 0.08–0.57 0.002
0.001 0.20 0.10–0.44 0.001
pendent beta-blocker use. †The efficacy of time-dependent beta-blocker therapy in reducing the
action term in the multivariate model. ‡Omnibus p value for testing the null hypothesis that all 4
value for testing the null hypothesis that all 4 HRs equal 1  0.014; p value for testing the nullor ofas a
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2 years of follow-up), further stressing the importance of
careful follow-up and timely therapeutic intervention in this
high-risk population.
Recurrent syncope as a predictor of subsequent fatal or
near-fatal events. Syncope, although nonfatal, is associ-
ted with comorbidities such as trauma and is a much more
requent cardiac event than ACA or SCD. The present
tudy supports previous data regarding the importance of
rst and recurrent syncope episodes as a powerful predictor
f subsequent fatal or near-fatal events in LQTS children
nd adolescents (8,9). We have shown that after the
ccurrence of a first syncope episode, LQTS patients
xhibited a 6-fold increase in the risk of subsequent ACA or
CD, and the risk of fatal or near-fatal events was increased
o 12-fold among patients who experienced 3 episodes
of syncope. These findings were independent of QTc
duration or age-sex interactions. Furthermore, patients who
had 3 or 4 episodes of syncope before the age of 20 years
(who composed approximately one-fifth of the total study
population and 43% of symptomatic patients) experienced a
very high rate of subsequent ACA or SCD during only 5
years of follow-up (in the range of 17% to 21%, regardless of
QTc duration). Thus, the occurrence of recurrent nonfatal
events has important prognostic implications in LQTS
patients that are independent of the traditional risk factors
previously reported in this population (1–3,7).
Therapeutic implications. The mainstay of LQTS treat-
ment in arrhythmia prevention is beta-blocker therapy,
which suppresses the adrenergic-mediated triggers (13).
Beta-blockers reduce cardiac event rates in LQT1 and
LQT2 patients in a risk-dependent fashion (14). Beta-
blockers were shown to reduce lethal events by 70% in
high-risk children (8) and by 64% in high-risk adolescents
with recent syncope (9). However, previous studies have also
suggested that beta-blocker therapy may have important
limitations in LQTS patients, including a relatively high
residual rate of cardiac events in patients with LQT2 and
LQT3 (2) and a high residual rate of ACA or SCD among
those who experience syncope during beta-blocker therapy
(15). Our study confirms that beta-blocker therapy is
associated with a significant reduction in the risk of a first
cardiac event in children and adolescents with LQTS (8,9).
Furthermore, our findings extend previous data and dem-
onstrate that treatment with beta-blockers is associated with
a pronounced (70%) reduction in the risk of subsequent
ACA or SCD among patients who experienced any number
of previous syncope episodes. However, we have shown that
the cumulative probability of ACA or SCD among patients
who experienced 2 syncope episodes was approximately
20% at 5 years of follow-up, despite the fact that the
majority of this population was treated with beta-blockers.
Thus, based on the findings of the present study and
previous reports, a management strategy among LQTS
patients who present for risk assessment after a syncope
episode may include the following: 1) initiation of beta-blocker therapy in those who experience a syncope event
without therapy (16); 2) additional interventions, including
primary ICD therapy (17) and/or left cardiac sympathetic
denervation (18–20) in patients who experience syncope
during beta-blocker therapy; 3) careful follow-up for resid-
ual symptoms or arrhythmias after the initiation of beta-
blocker therapy, with consideration of ICD therapy for
patients who experience 2 episodes of syncope during
follow-up (who had a frequency of ICD implants similar to
that of patients who experienced 1 or 2 episodes, but had a
very high rate of subsequent of ACA or SCD at 5 years
[approximately 20%]).
Study limitations. In analyzing recurrent syncope, we cen-
sored ACA and SCD in the cause-specific PWP model,
which may have biased subsequent risk group analyses. We
addressed this bias with a secondary analysis of predictors
for ACA or SCD, ensuring consistency in the risk analysis.
Data for the present study were derived from patients
enrolled in the International LQTS Registry. Thus, similar
to previous registry studies, it is possible that there were
some inaccuracies in the yearly data collection and an
inconsistent follow-up of some study patients. Furthermore,
despite the fact that cardiac events were reviewed carefully
by the study specialists, confounding factors, including
vasovagal, neurologic, and metabolic disturbances, cannot
be ruled out as the mechanism that precipitated some of the
syncope events in the present study.
It should be stressed that present findings regarding the
lack of association between QTc duration and the risk of
subsequent events are based on categorized data in a large
study population. Thus, individual clinical assessment for
therapeutic intervention is still important in this population
(i.e., an extremely prolonged QTc duration in a symptom-
atic individual may still be considered as an additional
marker for more aggressive intervention). Furthermore, it
should be noted that the implications regarding risk factors
for recurrent events that were identified in the present study
are restricted to children and adolescents who experience a
first syncope episode.
Our sample population had a more limited number of
genotyped patients (n  738), of whom the majority
composed the LQT1 and LQT2 genotypes. Therefore, risk
factors for recurrent events were not assessed for study
patients with the less frequent LQT3 through 8 genotypes.
Furthermore, due to a smaller sample size, we limited the
analyses of the genotype-specific models to a comparison
among risk factors for the first event and 2 cardiac events.
Conclusions
This study focused on recurrent syncope in children and
adolescents with LQTS. We have shown that the predictive
value of traditional LQTS risk markers change in patients
who experience a first nonfatal cardiac event. QTc duration
was shown to be a major predictor of a first syncope episode.
However, the risk associated with this traditional electro-
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LQTS and Recurrent Syncope February 22, 2011:941–50cardiographic marker was attenuated among patients who
experienced a first event. Furthermore, we have shown
important age-related genotype and sex differences in the
risk of recurrent events in LQT1 and LQT2 patients. These
time-dependent clinical and genetic factors should be con-
sidered in risk assessment and the management of LQTS
patients who present for evaluation after the occurrence of a
first episode of syncope.
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